Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 316

1.

Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study.

Tiede A, Priesack J, Werwitzke S, Bohlmann K, Oortwijn B, Lenting P, Eisert R, Ganser A, Budde U.

J Thromb Haemost. 2008 Apr;6(4):569-76. doi: 10.1111/j.1538-7836.2008.02909.x. Epub 2008 Jan 17.

2.

Clinical significance of inhibitors in acquired von Willebrand syndrome.

Mohri H, Motomura S, Kanamori H, Matsuzaki M, Watanabe S, Maruta A, Kodama F, Okubo T.

Blood. 1998 May 15;91(10):3623-9. Erratum in: Blood 1999 Jan 1;93(1):413.

4.

Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.

Lippi G, Franchini M, Salvagno GL, Montagnana M, Poli G, Guidi GC.

J Thromb Thrombolysis. 2008 Oct;26(2):150-3. Epub 2007 Sep 3.

PMID:
17786534
6.

A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.

Casonato A, Sartorello F, Pontara E, Gallinaro L, Bertomoro A, Grazia Cattini M, Daidone V, Szukowska M, Pagnan A.

Thromb Haemost. 2007 Dec;98(6):1182-7.

PMID:
18064311
7.
8.

Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo.

Geisen U, Zieger B, Nakamura L, Weis A, Heinz J, Michiels JJ, Heilmann C.

Thromb Res. 2014 Aug;134(2):246-50. doi: 10.1016/j.thromres.2014.04.033. Epub 2014 May 17.

PMID:
24891215
9.

Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.

Favaloro EJ, Lloyd J, Rowell J, Baker R, Rickard K, Kershaw G, Street A, Scarff K, Barrese G, Maher D, McLachlan AJ.

Thromb Haemost. 2007 Jun;97(6):922-30.

PMID:
17549293
10.

Acquired von Willebrand syndrome in patients with overt hypothyroidism: a prospective cohort study.

Stuijver DJ, Piantanida E, van Zaane B, Galli L, Romualdi E, Tanda ML, Meijers JC, Büller HR, Gerdes VE, Squizzato A.

Haemophilia. 2014 May;20(3):326-32. doi: 10.1111/hae.12275. Epub 2013 Oct 14.

PMID:
24118466
11.

Plasma and platelet von Willebrand factor abnormalities in patients with uremia: lack of correlation with uremic bleeding.

Casonato A, Pontara E, Vertolli UP, Steffan A, Durante C, De Marco L, Sartorello F, Girolami A.

Clin Appl Thromb Hemost. 2001 Apr;7(2):81-6.

PMID:
11292197
12.

Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).

Michiels JJ, Berneman ZN, van der Planken M, Schroyens W, Budde U, van Vliet HH.

Blood Coagul Fibrinolysis. 2004 Jun;15(4):323-30.

PMID:
15166918
13.

A highly-sensitive plasma von Willebrand factor ristocetin cofactor (VWF:RCo) activity assay by flow cytometry.

Chen D, Daigh CA, Hendricksen JI, Pruthi RK, Nichols WL, Heit JA, Owen WG.

J Thromb Haemost. 2008 Feb;6(2):323-30. Epub 2007 Nov 20.

14.

Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.

Michiels JJ, Budde U, van der Planken M, van Vliet HH, Schroyens W, Berneman Z.

Best Pract Res Clin Haematol. 2001 Jun;14(2):401-36. Review.

PMID:
11686107
15.

Laboratory diagnosis and molecular classification of von Willebrand disease.

Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ.

Acta Haematol. 2009;121(2-3):71-84. doi: 10.1159/000214846. Epub 2009 Jun 8. Review.

PMID:
19506352
16.

Lack of multimer organization of von Willebrand factor in an acquired von Willebrand syndrome.

Casonato A, Pontara E, Doria A, Bertomoro A, Cattini MG, Gambari PF, Girolami A.

Br J Haematol. 2002 Mar;116(4):899-904.

PMID:
11886398
17.

Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?

Favaloro EJ, Thom J, Patterson D, Just S, Dixon T, Koutts J, Baccala M, Rowell J, Baker R.

Thromb Res. 2009 Apr;123(6):862-8. doi: 10.1016/j.thromres.2008.10.008. Epub 2008 Dec 7.

PMID:
19064279
18.

Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease.

Favaloro EJ, Thom J, Patterson D, Just S, Baccala M, Dixon T, Meiring M, Koutts J, Rowell J, Baker R.

Blood Coagul Fibrinolysis. 2009 Sep;20(6):475-83. doi: 10.1097/MBC.0b013e32832da1ad.

PMID:
19584715
19.

Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification.

Budde U, Pieconka A, Will K, Schneppenheim R.

Semin Thromb Hemost. 2006 Jul;32(5):514-21.

PMID:
16862525
20.

Plasma collagen cofactor correlates with von Willebrand factor antigen and ristocetin cofactor but not with bleeding time.

Aihara M, Kimura A, Chiba Y, Yoshida Y.

Thromb Haemost. 1988 Jun 16;59(3):485-90.

PMID:
3142084

Supplemental Content

Support Center